Rhodiola rosea for Health & Longevity - Quick Reference Sheet

Rhodiola rosea for Health & Longevity

Created on 10/09/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Sonnet 5.5 – Audit

Rhodiola rosea, a plant-root extract sold as a dietary supplement to build resilience to stress, shows modest, short-lived effects. The clearest is a small endurance gain from a dose taken shortly before exercise; evidence for stress-related fatigue and mood is mixed. Lifespan claims rest on worms, flies and mice. Main concerns are mild side effects, slowed liver breakdown of some medicines and uneven product quality. (Full Review)

Protocol

Exercise, acute
About 200 mg
About 3% rosavin, 1% salidroside, 60 minutes before exercise
Stress-related fatigue (SHR-5)
576 mg/day for 28 days
Four tablets; another trial used one tablet (about 144 mg) daily for two weeks
Time of day
Morning to midday
Common practice; one trial gave one 200 mg tablet before breakfast and one before lunch
Time to effect
Endurance exercise
About 1 hour
Single dose tested before exercise
Life-stress symptoms
Within 3 days
Kept improving to week 4 in an open-label study
Anxiety symptoms
14 days
Lower self-reported anxiety than no treatment; no placebo

Benefits

Contraindications
  • People under 18 years of age
  • Pregnancy and lactation
  • Bipolar disorder (theoretical)
  • Monoamine oxidase (MAO) inhibitors (phenelzine; theoretical)
Key Interactions
  • Warfarin and phenytoin, caution (theoretical)
  • Losartan (blood-pressure drug), monitor
  • Other CYP2C9-cleared prescription drugs (celecoxib, glipizide), caution (theoretical)
  • Antidepressants (paroxetine), caution
  • Blood-pressure drugs (amlodipine, lisinopril) and glucose-lowering drugs (insulin, glipizide), monitor (theoretical)
  • Over-the-counter ibuprofen, caution (theoretical)
  • Supplements with additive effects (ashwagandha, St John's wort, 5-hydroxytryptophan, S-adenosylmethionine, guarana, yohimbine), monitor (theoretical)

Risk & Side Effects

  • High:
  • Medium: Reduced CYP2C9 Activity
  • Low: Mild Adverse Events; Product Adulteration & Contaminants; Serotonin-Related Symptoms with Antidepressants; Mania or Hypomania
  • Speculative: Blood Pressure or Glucose Lowering

Monitoring

Marker Target Why
Blood pressure (seated, home) No established target; track change from own baseline Safety check: lowering with blood-pressure drugs
Fasting glucose 70–99 mg/dL (standard reference range) Safety check: low blood sugar with glucose-lowering drugs
INR (international normalized ratio) 0.8–1.2 without anticoagulants (blood thinners; standard reference range); prescriber-set target on warfarin Safety check: CYP2C9 inhibition may raise warfarin effect

Cadence: Blood pressure rechecks at 1 week and 4 weeks, then every 3 months during continued use; fasting glucose rechecks on the same schedule for users of glucose-lowering medicine; INR recheck 1–2 weeks after starting for warfarin users; repeat questionnaires at 4 and 12 weeks

Qualitative Assessment

  • Fatigue and energy on a validated scale (burnout or vitality questionnaire)
  • Perceived stress and mood, including anxiety
  • Sleep quality and daytime alertness
  • Exercise effort and time to exhaustion, if used for training
  • Side effects: dizziness, dry mouth, restlessness, sleep disruption